Format
Sort by
Items per page

Send to

Choose Destination

Best matches for hemophilia:

Hemophilia and oral health. Zaliuniene R et al. Stomatologija. (2014)

Haemophilia B: Where are we now and what does the future hold? Dolan G et al. Blood Rev. (2018)

Haemophilia. Brody H et al. Sci Am. (2015)

Search results

Items: 1 to 20 of 28944

1.

Physiotherapy outcome measures of haemophilia acute bleed episodes: What matters to patients?

Bradshaw E, McClellan C, Whybrow P, Cramp F.

Haemophilia. 2019 Sep 15. doi: 10.1111/hae.13840. [Epub ahead of print]

PMID:
31522466
2.

Newly diagnosed hemophilia in an older adult.

Cornia PB.

Am J Med. 2019 Sep 11. pii: S0002-9343(19)30751-X. doi: 10.1016/j.amjmed.2019.08.028. [Epub ahead of print] No abstract available.

PMID:
31520617
3.

Adherence to prophylactic treatment.

Torres-Ortuño A.

Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S19-S21. doi: 10.1097/MBC.0000000000000822.

PMID:
31517712
4.

Prophylactic treatment in hemophilic patients with inhibitors.

Haya S.

Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S14-S18. doi: 10.1097/MBC.0000000000000823.

PMID:
31517711
5.

Surgical approaches to hemophilic arthropathy.

Rodriguez-Merchan EC.

Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S11-S13. doi: 10.1097/MBC.0000000000000824.

PMID:
31517710
6.

Sequelae of repeated lesions in persons with hemophilia.

Querol F.

Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S7-S10. doi: 10.1097/MBC.0000000000000820. No abstract available.

PMID:
31517709
7.

Clinical pattern of hemophilia and causes of variability.

Mingot-Castellano ME.

Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S4-S6. doi: 10.1097/MBC.0000000000000821.

PMID:
31517708
8.

A history of prophylaxis in haemophilia.

Moreno MM, Cuesta-Barriuso R.

Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S1-S3. doi: 10.1097/MBC.0000000000000844.

PMID:
31517707
9.

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement.

Tiede A, Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d'Oiron R, Benchikh El Fegoun S, Kessler CM.

Haemophilia. 2019 Sep 13. doi: 10.1111/hae.13844. [Epub ahead of print]

PMID:
31517435
10.

A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.

Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A, Suzuki T, Taki M.

Haemophilia. 2019 Sep 12. doi: 10.1111/hae.13848. [Epub ahead of print]

PMID:
31515851
11.

Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.

Gao C, Schroeder JA, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, Czechowicz A, Shi Q.

Blood Adv. 2019 Sep 24;3(18):2700-2711. doi: 10.1182/bloodadvances.2019000516.

12.

Clinical and laboratory diagnosis of rare coagulation disorders (RCDs).

Menegatti M, Palla R.

Thromb Res. 2019 Sep 7. pii: S0049-3848(19)30402-5. doi: 10.1016/j.thromres.2019.09.006. [Epub ahead of print]

PMID:
31515069
13.

Inhibitor eradication and bleeding management of acquired hemophilia A: a single center experience in China.

Ye N, Liu Z, Xu G, Wang X, Wu F, Xu X, Wu W.

Hematology. 2019 Dec;24(1):631-636. doi: 10.1080/16078454.2019.1663028.

PMID:
31514689
14.

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.

Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG.

Thromb Res. 2019 Aug 26;183:13-19. doi: 10.1016/j.thromres.2019.08.023. [Epub ahead of print]

PMID:
31513978
15.

Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.

Castaman G, Borchiellini A, Santagostino E, Tagariello G, Serban M, Uscatescu M, Truica C, Albert F, Morfini M.

Haemophilia. 2019 Sep 11. doi: 10.1111/hae.13828. [Epub ahead of print] No abstract available.

PMID:
31509326
16.

Potential of the Community Counts registry to characterize rare bleeding disorders.

Gupta S, Acharya S, Roberson C, Lail A, Soucie JM, Shapiro A.

Haemophilia. 2019 Sep 11. doi: 10.1111/hae.13847. [Epub ahead of print]

PMID:
31509320
17.

Pseudotumours in haemophilia: non-adherence, under-reporting bleeds or bad luck?

Mezhov V, Campbell S, Powell A, Tran H.

Intern Med J. 2019 Sep;49(9):1171-1173. doi: 10.1111/imj.14433.

PMID:
31507049
18.

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.

Jankowski W, McGill J, Lagassé HAD, Surov S, Bembridge G, Bunce C, Cloake E, Fogg MH, Jankowska KI, Khan A, Marcotrigiano J, Ovanesov MV, Sauna ZE.

Blood Adv. 2019 Sep 10;3(17):2668-2678. doi: 10.1182/bloodadvances.2019000338.

19.

Total Hip Arthroplasty in Patients with Coagulopathy.

von Roth P, Thiele K.

Z Orthop Unfall. 2019 Sep 10. doi: 10.1055/a-0902-5362. [Epub ahead of print] English, German.

PMID:
31505698
20.

Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A.

Pasca S, Zanon E.

Thromb Res. 2019 Aug 26;183:1-3. doi: 10.1016/j.thromres.2019.08.022. [Epub ahead of print]

PMID:
31505377

Supplemental Content

Loading ...
Support Center